Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWJ1453
- Development stage
- Preclinical
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWJ1453 is a fixed-dose combination (FDC) therapy being developed by Daewoong Pharmaceutical for the simultaneous management of hypertension and dyslipidemia. The drug is formulated as a solid oral dosage form. While the specific active pharmaceutical ingredients (APIs) are not explicitly disclosed in public pipeline summaries, Daewoong's development strategy in this therapeutic area typically involves combining an angiotensin II receptor blocker (ARB) or a calcium channel blocker (CCB) with a statin (HMG-CoA reductase inhibitor). The program aims to improve patient compliance and therapeutic outcomes by reducing the pill burden for patients with co-existing cardiovascular risk factors.
Beyond the preview
Go deeper on DWJ1453.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWJ1453.